Our Platform

VBL is pioneering a new class of drugs called Lecinoxoids to treat immune-inflammatory conditions. Using its unique drug discovery capabilities, VBL Therapeutics has developed a series of proprietary phospholipids analogs from the Lecinoxoid family that are rationally designed as orally available anti-inflammatory medicines to address the substantial unmet needs in immune-inflammatory diseases, including psoriasis, rheumatoid arthritis, multiple sclerosis, inflammatory bowel disease and atherosclerosis.